---
schema_version: "secwatch.filing_event.v1"
accession: "0001372514-26-000048"
form_type: "8-K"
ticker: "KPRX"
cik: "0001372514"
company_name: "KIORA PHARMACEUTICALS INC"
filed_at: "2026-05-08T23:59:59+00:00"
generated_at: "2026-05-14T19:56:52.021142+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Kiora Q1 cash $13.9M, $5.0M equity raise post-quarter; KIO-301 enrollment nearly 50% in Phase 2

## Summary
- Q1 cash $13.9M; post-quarter raised $5.0M in equity from Perceptive Advisors; operational runway into late 2028.
- Phase 2 ABACUS-2 enrollment for KIO-301 nearly 50% completed; trial sites expanding due to strong patient demand.
- ABACUS-1 results published in Nature Medicine, validating KIO-301 photoswitch technology for vision restoration.
- Phase 2 KLARITY study of KIO-104 progressing; safety review upcoming to enable dose escalation.
- R&D expenses $2.1M with $1.2M Théa reimbursement; G&A $1.6M; collaboration receivables $1.5M.

## SEC filing metadata
- accession: 0001372514-26-000048
- form_type: 8-K
- ticker: KPRX
- cik: 0001372514
- company_name: KIORA PHARMACEUTICALS INC
- filed_at: 2026-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1372514/000137251426000048/0001372514-26-000048-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1372514/000137251426000048/kprx-20260508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001372514-26-000048
- JSON: https://secwatch.observer/filing/0001372514-26-000048.json
- Plain text: https://secwatch.observer/filing/0001372514-26-000048.txt

## Source-grounded claims
- claim_id: aefb3e23dec8c0b326880a08e00a858f1eb836d5
  claim: KIORA PHARMACEUTICALS INC reported financial results for the first quarter ended March 31, 2026.
  evidence_excerpt: On May 8, 2026, Kiora Pharmaceuticals, Inc. (the “Company”) issued a press release announcing financial results for the quarter ended March 31, 2026 and an update on clinical development progress.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1372514/000137251426000048/0001372514-26-000048-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.